I hereby certify that this correspond an envelope addressed ce is being deposited with the US Postal Service with sufficient postage as First Class Mail in Stop Amendment, Commissioner for Patents, P.O box 1450, Alexandria, VA 22313-1450, on the date shown below. Date: November 16, 2006

> **PATENT** Docket No. GC800-2-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Jones et al.)) Group Art Unit:)
Serial No.: 10/555,587) Examiner: Unassigned
Filed: May 12, 2004)
For: Novel Lipolytic Enzyme ELIP)

Supplemental Information Disclosure Statement

Mail Stop Amendment Commissioner for Patents P.O Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449 and attached thereto) of which they are aware, that they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information

on Disclosure Statement:
(a) accompanies the new patent application submitted herewith. 37 CFR §1.97(a).
(b) is filed within three months after the filing date of the application or within three months after the date of entry into the national stage of a PCT application as set forth in 37 CFR §1.491.
(c) \boxtimes as far as is known to the undersigned, is filed before the mailing date of first Office Action on the merits.
(d) is filed after the first Office Action and more than three months after the

	as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and is accompanied by either the fee (\$180.00) set forth in 37 CFR §1.17(p) or a certification as specified in 37 CFR §1.97(e), as checked below. Authorization to charge Deposit Account No. 07-1048 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement is provided in the Transmittal Letter submitted herewith in duplicate.						
	(e) is filed after the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by authorization (in the Transmittal Letter submitted herewith in duplicate) to charge Deposit Account No. 07-1048 the fee (\$180.00) set forth in 37 CFR §1.17(I)(1) and a certification as specified in 37 CFR §1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the Supplemental Information Disclosure Statement.						
•	oxes (d) or (e) is checked above, the following "certification" under 37 CFR						
§1.97(e) may	need to be completed.] The undersigned certifies that:						
	Each item of information contained in the Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.						
	No item of information contained in this Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.						
A copy of the	items on Form PTO-1449 is supplied: PCT International Search Report for PCT/						
US200401468	35, filed May 12, 2004 with attached patents and publications.						
☐ ead	ch 🗵 none 🗌 only those listed below:						
A concise exp	lanation of relevance of the items listed on PTO-1449 is:						
	not given						
	given for each listed item						
	given for only non-English language listed item(s)						
in the form of an English language copy of a Search Report fro foreign patent office, issued in a counterpart application, which refers t relevant portions of the references.							

Attorney Docket No. GC800-2-US

Page 3

The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Janet Kaiser Castaneda Registration No. 33,228

Date: November 16, 2006

Genencor International, Inc. 925 Page Mill Road Palo Alto, CA 94304-1013

Tel: 650 846-7615 Fax: 650 845-6504

INFORMATION DISCLOSURE CITATION									
Attorney Docker	torney Docket No.: GC800-2-US Serial No.: 10/555,587								
Applicant: Jone	s et al.	2006							
Filing Date: May	y 12, 2004 \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	1 5 0 5000 PA		Group: 1652					
Page 1 of	1 3	ð/		Date of this Submission:	November 16,	2006			
Page 1 of 1 Date of this Submission: November 16, 2006 US PATENT DOCUMENTS									
Examiner's	Document					Sub-	Filing		
Initial	Number	Date	Name	· · · · · · · · · · · · · · · · · · ·	Class	Class	Date		
		FOR	EIGN PATENT	T DOCUMENTS					
Examiner's	Document					Sub-	Translation		
Initials	Number	Date	Country		Class	Class	Yes/No		
	WO 93/09219	05/13/93	PCT						
	WO 04/101763	11/25/06	PCT						
	WO 04/101759	11/25/06	PCT						
			OTHER DOO	UMENTS	· · · · · ·				
Examiner's									
Initials	Author, Title, Date, Pertinent Pages, etc.								
	Database Embl – 22 March 2001 – "NF082F11PL1F1093Phosphate starved leaf Medicago truncatula cDNA clone NF082F11PL5', mRNA sequence. »Database accession no. BG45687 Abstract								
	Jaeger et al., "Bacterial biocatalysts: molecular biology, three-dimensional structures, and biotechnological applications of lipases." Annual Review of Microbiology, (1999) V. 53, pp.315-351								
	Copy of the Supplementary European Search Report								
	<u></u>								

				· · · · · · · · · · · · · · · · · · ·					
				· · · · · · · · · · · · · · · · · · ·	·				
	41			u 1830-11					
									
					<u> </u>				
Fuenines	/Tekchand Saidha	<u> </u>		Date Considered	1/04/2008				
Examiner	7 Tekchana Galone	21		Date Considered					
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in									
conformance and not considered. Include copy of this form with next communication to applicant. PTO-1449									